Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic olanzapine for opioid-induced nausea and vomiting in patients with cancer
jRCTs031220008Active, not recruiting
- Sponsor
- Japanese Society for Palliative Medicine
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of olanzapine in Opioid-induced nausea and vomiting (OINV), sponsored by Japanese Society for Palliative Medicine. Primary endpoint: Complete control rate. Started Jun 2022; status: active, not recruiting.
02
Drugs
olanzapine
03
Conditions
Opioid-induced nausea and vomiting (OINV)
Beyond the preview
Go deeper on jRCTs031220008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220008.